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Abstract
Background: To determine the use of antidepressants (ADs) in people with sub-threshold depression (SD); the
lifetime prevalence of mania and hypomania in SD and the link between ADs use, bipolarity and anxiety disorders
in SD.
Methods: Study design: community survey. Study population: samples randomly drawn, after stratification from the
adult population of municipal records. Sample size: 4999 people from seven areas within six Italian regions. Tools:
Questionnaire on psychotropic drug consumption, prescription; Structured Clinical Interview NP for DSM-IV
modified (ANTAS); Hamilton Depression Rating Scale (HAM-D); Mood Disorder Questionnaire (MDQ); Short Form
Health Survey (SF-12). SD definition: HAM-D > 10 without lifetime diagnosis of Depressive Episode (DE).
Results: SD point prevalence is 5.0%. The lifetime prevalence of mania and hypomania episodes in SD is 7.3%.
Benzodiazepines (BDZ) consumption in SD is 24.1%, followed by ADs (19.7%). In SD, positive for MDQ and comorbidity
with Panic Disorder (PD) or Generalized Anxiety Disorders (GAD) are associated with ADs use, whereas the association
between a positive MDQ and ADs use, without a diagnosis of PD or GAD, is not significant. Only in people with DE the
well-being (SF-12) is higher among those using first-line antidepressants compared to those not using any medication.
In people with SD no significant differences were found in terms of SF-12 score according to drug use.
Conclusions: This study suggests caution in prescribing ADs to people with SD. In people with concomitant
anxiety disorders and SD, it should be mandatory to perform a well-designed assessment and evaluate the
presence of previous manic or hypomanic symptoms prior to prescribing ADs.
Background
Patients with mild-to-moderate, chronic or episodic dys-
thymia and anxiety may not benefit greatly from antide-
pressant treatment [1]. According to this study,
antidepressants have limited short-term efficacy in uni-
polar depressive disorders and even less in acute bipolar
depression. Moreover their long-term prophylactic effec-
tiveness in recurrent unipolar major depression remains
uncertain and is doubtful in bipolar depression [1].
These limitations may, in part, reflect the excessively
broad concept of unipolar depression. The current
subtyping of depression is based on the DSM-IV-TR
categorical division of bipolar and depressive disorders.
Current evidence, however, supports a dimensional
approach to depression, as a continuum/spectrum of
overlapping disorders, ranging from bipolar I depression
to major depressive disorder [2].
Treatment-refractory depression may reflect failure to
distinguish depressive conditions, particularly in bipolar
disorder, that are inherently less responsive to antide-
pressants. Antidepressants probably should be avoided
in bipolar depression, mixed manic-depressive states,
and in neurotic depression. Expectations of beneficial
effects of antidepressant treatments for specific types of* Correspondence: mgcarta@tiscali.it
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patients with symptoms of depression or anxiety require
critical re-evaluation.
Taking into account the hypothesis that in sub-thresh-
old depressions (SDs) the use of antidepressants may be
ineffective, this study aims to examine this hypothesis in
a large community sample:
1) The amount of use of antidepressants in people
with depressive symptoms (HAM-D > 10) without
lifetime diagnosis of Depressive Episode (DE).
2) The lifetime prevalence of mania and hypomania
in such subjects.
3) The role of anxiety disorders in the use of antide-
pressants in people with SD.
4) The link between antidepressants use, bipolarity
and anxiety disorders in SD.
5) Whether or not subjects with SD treated with
antidepressants actually need to be treated.
Methods
Design
The study is a community survey based on the database
of the National Italian Survey “The use of antidepres-
sants in Italy” [3]. Face-to-face interviews were carried
out at candidates’ homes.
Recruitment methods and study sample
The study sample was randomly drawn from the adult
population of municipal records in seven different areas
from different Italian locations with wide variations in
socio-economic conditions: [a] Sicily (Catania), [b] Sardi-
nia (Iglesias), and [c] Puglia (Bari) in southern Italy; [d]
Abruzzo (L’Aquila) and [f] Tuscany (Florence and Pisa)
in central Italy; [g] Friuli-Venezia Giulia (Udine) in
northern Italy. In each area, both urban and rural sub-
areas were selected. The sample of Florence (Sesto-Fior-
entino) was only urban and Pisa was only rural. A third
of the sample in each centre was drawn from three var-
iously populated municipalities; less than 2,000, from
2,001 to 10,000 inhabitants, and from 10,001 to 20,000
inhabitants.
Randomization was performed after stratification by sex
and four different age groups (18-24; 25-44; 45-64; > 64).
Using the above mentioned methodology, a sample of
4999 people was drawn from the seven areas. The size
of the subsamples were: 704 in L’Aquila; 971 in Bari;
666 in Catania; 846 in Florence; 465 in Iglesias; 464 in
Pisa, and 882 in Udine.
Subjects were contacted at home by phone or by mail
by the local coordinator of the study.
Interview, tools and study assessment
Interviews were carried out using the following tools:
1. Ad-hoc form to assess basic demographic data
and psychotropic drug consumption, prescription
circumstances and health-services utilization pre-
viously used and validated in a regional survey [4].
For all the subjects, consumption of antidepressant
drugs was ascertained. Positive use was identified as
subjects consuming antidepressant drugs at thera-
peutic dosages for every day for at least 15 days
prior to the interview.
2. The “Advanced Neuropsychiatric Tools and
Assessment Schedule” (ANTAS), a computerized
semi-Structured Clinical Interview derived from the
non patient version (SCID-I/NP) for DSM-IV [5] to
assess the presence of psychiatric disorders (this, as
stated in the study protocol, requires a clinical com-
petence to administer). A reliability study of the
diagnosis derived from the ANTAS compared to
SCID has been carried out and the results have been
previously published [6]. The results for mood and
anxiety diagnosis with SCID showed a mean k of
0.85 [3,6].
3. The Mood Disorder Questionnaire (MDQ) ([7],
Italian version [8]) for the assessment of bipolar
spectrum disorders.
4. The depressive symptoms were measured by
means of Hamilton Depression Rating Scale (HAM-
D), [9].
5. Quality of life was evaluated with the Short Form
Health Survey (SF-12) [10]. The SF-12 includes the fol-
lowing dimensions: physical activity, physical health
limitations on role or activities, emotional state, physi-
cal pain, self-evaluation of general state of health, vital-
ity, social activity and mental health. The period of
measurement is the previous month. Highest scores
correspond to better conditions and quality of life.
For the purpose of the present study we used
these definitions:
1. SD = people having, at the time of the inter-
view, depressive symptoms (HAM-D score > 10)
without an ANTAS-SCID-DSM-IV lifetime diag-
nosis of Depressive Episode.
2. Depressive Episode (DE) point prevalence =
people with an ANTAS-SCID-DSM-IV Depres-
sive Episode diagnosis at the time of the inter-
view; they may have a lifetime ANTAS diagnosis
of Major Depressive Disorder (MDD) or Bipolar
Disorder (BD).
3. Not Depressed (ND) people = people not
showing any relevant depressive symptoms at the
time of the interview (HAM-D score < 10).
4. Lifetime diagnosis of manic-hypomanic epi-
sode in SD = people having MDQ lifetime posi-
tivity (score > 7).
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All the people interviewed in the community were
included in the analysis.
Interviewers and training
Interviewers were selected from psychologists and physi-
cians with at least two years of experience in clinical
psychiatric work following graduation.
They received a common and intensive training in the
use of the research instrument and administration of
home interviews by the Coordinating Unit.
Interviewers were provided with a laptop computer
and software to record data during the interview.
Two assistant researchers from the Coordinating Unit
traveled to each field unit and interviewed at least seven
patients and three control subjects who had been inter-
viewed by the local interviewers. Differences in results
were discussed and resolved. The diagnosis reliability
between coordinator researchers and each unit had a k
mean higher than 80.
Monitoring and Quality Control
Interview quality was monitored by cross-examining the
interviewers every three months and having at least 120
interviews repeated by different interviewers.
Sample Size
It was envisaged that from 60% to 65% of the original sam-
ple (a planned sample of at least 4,800 interviews) would
take part in the survey (5% of members were expected to be
deceased or moved, 10% were expected to be non retrieva-
ble and 20% were considered the refusal rate) for an
expected total of about 3,000 interviewed subjects. This
sample size was expected to provide a 95% confidence inter-
val of ± 0.036% of the expected prevalence summary esti-
mate of 4% of both antidepressant consumption and bipolar
disorders as MDQ positives (relative standard error being
around 7%). This sample was also planned for recording SD
(main objective of the present study), considering that the
expected point prevalence of SD was 6-9%. This is because,
the ECA study of Judd and Coll [11] found a prevalence of
11.8% using a less inclusive diagnosis. A similar frequency
was also found in the Zurich study by Angst and Coll [12].
Ethical Aspects
An informed consent for the use of anonymous data
suitable for an aggregate study was signed by each can-
didate. The study was approved by the ethical commit-
tee of the Italian National Health Institute (Rome). Data
were not nominal at source and each subject was identi-
fiable with a code number.
Results
The characteristics of the enrolled sample by age, sex
and the rate of non-interviewed have been already
published [3]. No significant statistical differences were
found between the interviewed sub-samples and the ran-
domized sub-samples according to age and sex [3].
A total sample of 3389 subjects was enrolled (57.7%
female).
Table 1 shows the prevalence of SD by sex in the total
sample. At the time of interview, 5.0% of the sample had
SD. SD is more frequent in females than in men (5.5%
vs 2.0%, OR = 2.86 CL95% 1.4-4.3). The prevalence of
lifetime mania and hypomania episodes in people with
SD is 7.3% (6.5 in females, 10.5 in males). The table
shows that the prevalence of mania and hypomania in
SD is lower than in people with DE but higher than in
the overall sample without depressive symptomatology
(SD or DE) at the time of the interview.
Table 2 shows the psychoactive drugs and other treat-
ments consumed by people with SD in the overall sam-
ple and by sex. Benzodiazepines (BDZ) are the drugs
with highest consumption (24.1%) followed by antide-
pressants (19.7%). First line antidepressants (including
SSRI, TCA, IMAO, SNRI, NaSSA and Bupropion) are
used by 14.6% of the sample and second line antidepres-
sants (low-dosage Benzamides, low-dosage Quetiapine,
Trazodone, Nefazodone, Adenosin-methionine and
Hypericum Perforatum) by the remaining 5.1%. We
note that low-dosage Benzamides are available for
minor depression only in Italy. Psychotherapies are well
represented (9.5%) and homeopathic treatments are lim-
ited (2.9%). The use of antidepressants and benzodia-
pines is more frequent among females with SD than
among males with SD, but the difference is not statisti-
cally significant.
When we compare the use of psychoactive drugs and
other treatments in the overall sample, in ND subjects,
subjects with DE point prevalence and in subjects with
SD (Table 3), the frequencies of use of first-line and sec-
ond-line antidepressants rank as follows: subjects with
DE > STD > ND. Treatments with BDZ and psychother-
apy do not show any difference between DE and STD,
but these two groups show higher use than ND people.
Homeopathic treatments seem to be typically used in
SD with a statistically significant difference only when
compared to ND people.
No demographic factors (sex, age, geographic distribu-
tion) appear to be of relevance in the frequency of pre-
scription of antidepressants in the SD sample (Table 4).
Of relevance, in people with SD, a positive MDQ diag-
nosis is associated with antidepressant use (the calcula-
tion was carried out after standardizing for sex and age).
Comorbidity with PD or GAD is also associated with
the use of antidepressant drugs. Re-calculating the
weight of the association between MDQ positivity and
antidepressants use, standardizing by having a diagnosis
of PD or GAD, the significance of association disappears
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(c2 = 1.6 (1df), p = 0.2, OR = 2.6). Thus, the basis for
taking antidepressants is the anxiety disorder and MDQ
positivity is probably occurring as a confounding factor.
Table 5 analyzes the well being of the subjects in the
sample, measured with SF-12, according to the diagnosis
and the treatment of BDZ and antidepressants. In the
community, only in people with DE the well-being is
higher in those using first-line antidepressants compared
to those not using any medication. Moreover, no differ-
ences are observed for the second-line antidepressants
or BDZ. In people with SD no differences are found
even for first-line antidepressant.
Discussion
The study indicates that around 5% of people in the
community have SD and that SD is higher in women
than in men (5.5 vs 2%). People with SD have a life-
time prevalence of manic and hypomanic episodes
detected by MDQ (7.3%). This frequency falls in the
middle, between people without depression (DE or SD)
at the time of interview (2.4%) and people with DE
(27.3%). If we consider that SD is more prevalent than
DE in the community (5% vs 2.4%), the relevance of
MDQ positivity at the community level is quite similar
in DE (MDQ positivity 0.4% of the whole community
sample) and in SD (MDQ positivity 0.3% of the
sample). This is an interesting point because it is intui-
tive that the identification of a previous manic or
hypomanic episode should be easiest in people with a
clear diagnosis of DE.
For the purpose of this study we decided to compare
the lifetime prevalence of MDQ Positivity in people
showing symptoms of DE without a lifetime diagnosis of
DE and in people with DE at the time of interview. Our
purpose is to define how much is of clinical and public
health relevance if a person with depressive symptoms
at the time of a hypothetical clinical contact but without
prior diagnosis of depressive episode has manic or hypo-
manic lifetime episode and how much this phenomenon
may be related with the antidepressants use. In this
sense the definition of SD as people having a HAM-D
score of > 10 is an operational choice for detecting peo-
ple without diagnosis of DE but with a relevant depres-
sive symptomatology that may result in antidepressant
prescription.
We take into account that the diagnosis of Mania and
Hypomania by SCID may be too restrictive [13] and we
also use the MDQ positivity to measure the “bipolarity
spectrum”. The under recognition of BD in people with
DE is not the specific objective of this study; this topic
has been addressed in another study using the same
database [14].
Table 1 Prevalence of Sub-threshold Depression (SD) (HRDS > 10 without criteria for lifetime Depressive Episode) by
sex and frequency of Mania and Hypomania detected by MDQ in SD, Depressive Episode point prevalence = DE and
in the overall sample without depressive depression (SD or DE) = ND, by sex
Male % Female % Total % OR (F) CL 95% Χ2 1df P
SD 29 2.0 108 5.5 137 5.0 2.86 1.4-4.3 25.5 < 0.0005
1. MDQ in SD 3 10.3 7 6.5 10 7.3 0.6 0.24-1.39 0.10 0.76
2. MDQ in DE 4 23.5 11 28.9 15 27.3 1.3 0.41-2.10 0.01 0.92
3. MDQ in ND 42 3.0 36 2.0 78 2.4 0.6 0.34-1.05 3.14 0.08
MDQ in the overall sample 49 3.4 54 2.7 103 3.0 0.8 0.5-1.2 1.00 0.312
Χ2 by columns
3df
25.7 107.0 100.4
P 0.0001 0.0001 0.0001
Homogeneity by cells in columns (1DF):
Column Male 1vs2, c2 = 0.6, P = 0.43; 1vs3, c2 = 2.86, P = 0.09; 2vs3 c2 16.3, P < 0.001; Column Female1vs2, c2 = 11.1, P < 0.001; 1vs3, c2 = 7.05, P = 0.006;
2vs3 c2 = 98.8, P < 0.0001; Column Total 1vs2, c2 = 12.5, P < 0.001; 1vs3, c2 = 6.4, P < 0.01; 2vs3 c2 = 91.2, P < 0.0001.
Table 2 Psychoactive drugs and other treatments in Sub-threshold Depression (HRDS > 10 without lifetime criteria for
Depressive Episode) by sex
Treatment Males % Females D % Total (males and females) % OR (F) CL 95% Χ2 1df P
First-line Antidepressants° 2 6.8 18 16.6 20 14.6 2.7 0.1-96.4 1.05 0.30
Second-line Antidepressants§ 1 3.4 6 5.6 7 5.1 1.6 0.1-31.2 0.1 0.98
Benzodiazepines* 7 24.1 33 30.6 40 24.1 1.4 0.2-6.3 0.2 0.66
Homeopathics 1 3.4 3 2.7 4 2.9 0.8 0.3-2.1 0.2 0.68
Psychotherapy 3 10.3 10 9.2 13 9.5 0.9 0.4-2.0 0.1 0.86
°SSRI, TCA, IMAO, SNRI, NaSSA, bupriopion; § low-dosage benzamides, low-dosage quetiapine, trazodone, nefazodone, Adenosin-methionine, Hypericum
Perforatum
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The results of our community study show that people
with SD use largely the first- (14.6%) and the second-
line antidepressants (5.1%), as well as BDZ (24.1%). The
consumption of antidepressants is similar in people with
SD and DE, only smaller for the first-line antidepres-
sants but higher for all other medications than in people
without depressive symptoms. The use of antidepres-
sants in SD is more significant with comorbidity factors
PD or GAD as per treatment guidelines, indicating anti-
depressants as the first-line of treatment for PD [15,16]
and GAD [17].
Nevertheless in our community sample, the diagnoses
of PD or GAD are strictly associated with MDQ positiv-
ity. This is expected given the recent findings in a recent
study [18] determining any confounding relationship
between MDQ positivity and antidepressant use in peo-
ple with SD. In fact, antidepressants are frequently used
in the sub-sample with a previous manic or hypomanic
episode, detected by MDQ, with a high risk for develop-
ing BD (even without a DE).
Depressive episodes are the most prevalent component
in bipolar disorders, even when, as in a community, they
are showing a clinical picture not meeting criteria for
DE. There is a growing awareness that treatment of
bipolar depression is one of the greatest challenges in
modern psychiatry [19,20] since response to antidepres-
sants is often unsatisfactory despite the overuse of these
agents [19]. Other studies also suggest that treating
bipolar depression with antidepressants is likely a bad
practice [20,21]. There is indeed a strong rationale for a
cautious approach to antidepressant use in bipolar dis-
order [18,22], which is based on the following findings:
(i) The risk of antidepressant-induced mood-cycling
is high [23].
(ii) Antidepressants have not been shown to defini-
tively prevent suicides and reduce
mortality, unlike long-term lithium treatment [24].
(i) Antidepressants have been shown less effective
than mood stabilizers or atypical antipsychotics in
acute bipolar depression and less effective than
mood stabilizers in preventing depressive relapse in
BD. A recent systematic review and meta-analysis,
reexamining the efficacy and safety of antidepres-
sants use for acute treatment of bipolar depression,
found antidepressants not statistically superior to
placebo or other current standard treatment for
bipolar depression [25].
European guidelines exert a more flexible attitude
towards the use of antidepressants, whereas currently
published American guidelines explicitly do not recom-
mend antidepressants in the treatment of bipolar
depression, unless the depressive episode is severe [26].
Our study indicates that antidepressants are broadly
used (20% of people) in a large community subsample
with SD and is strictly associated with bipolar disorders
with the possible induction of mood-cycling in the sub-
sample.
Table 3 Comparison of psychoactive drugs use and other treatments in Sub-threshold Depression (HRDS > 10 without
criteria for lifetime Depressive Episode) = SD; subjects with Depressive Episode point prevalence = DE and in the
overall sample without Depression (SD or DE) = ND
2. SD 3. DE 1. ND Overall Sample Χ2 2DF P
Total 137 (4.0) 55 (1.6) 3206 (94.3) 3398
°First line Antidepressants 20 (14.6) 17 (30.9) 69 (2.1) 106 (3.1) 210.2 0.0001
§Second line Antidepressants 7 (5.1) 14 (25.4) 32 (1.0) 53 (1.6) 14.7 0.0001
*Benzodiazepines 40 (29.1) 14 (25.4) 188 (5.8) 242 (7.1) 147.9 0.0001
°°Homeopathics 4 (2.9) 0 21 (0.6) 25 (0.7) 8.1 0.018
**Psychotherapies 13 (9.5) 8 (17.8) 50 (1.5) 71 (2.1) 95.3 0.0001
°Homogeneity by cells: 1vs2, c2 = 74.1, 1DF P < 0.0001; 1vs3, c2 = 205.7, 1DF P < 0.0001; 2vs3 c2 = 9.8, 1DF 0.002; §Homogeneity by cells: 1vs2, c2 = 12.5, 1DF
P < 0.0001; 1vs3, c2 = 76.3, 1DF P < 0.0001; 2vs3, c2 = 14.6, P < 0.0001; 2vs3 c2 = 5.6, 1DF P = 0.018; * Homogeneity by cells: 1vs2, c2 = 109.4, 1DF P < 0.0001;
1vs3, c2 = 44.5, 1DF P < 0.0001; 2vs3 c2 = 0.1, 1DF NS; °° Homogeneity by cells: 1vs2, c2 = 4.6, 1DF P < 0.031; 1vs3, c2 = 0.1, 1DF NS; 2vs3 c2 = 0.3, 1DF NS; **
Homogeneity by cells: 1vs2, c2 = 40.4, 1DF P < 0.0001; 1vs3, c2 = 45.0, 1DF P < 0.0001; 2vs3 c2 = 0.5, 1DF NS
Table 4 Determinants of all ADs (first and second line)
prescriptions in Sub-threshold Depression (HRDS > 10
without criteria for lifetime Depressive Episode)
N(%) OR 95% CI c2 P
Females 24 (22.2) 2.4 0.5-10.6 1.3 0.244
North-Center 20 (23.8) 2.0 0.7-6.0 1.7 0.194
Age 18-24 2 (10.0) 1.01 0.95-1.1 0.1 0.6
Age 25-64 19 (17.4) 0.5 0.9-1.3 1.1 0.291
Age > 64 6 (33.3) 2.3 0.6-8.8 1.5 0.214
*MDQ > 7 7.5 (41.7) 3.6 1.1-40.5 4.8 0.028
*Comorbidity PD 9.6 (53.3) 17.2 6-49.2 27.2 0.0001
*Comorbidity DOC 2.8 (40.0) 2.9 0.5-1.3 0.8 0.369
*Comorbidity GAD 6.9 (43.1) 4.2 1.2-13.8 5.6 0.018
*Standardized by age, sex and residence (N/S); °Vs overall sample receiving
ADs (with exclusion of DE point prevalence)°°The Odds Ratio is calculated vs
all other age frequencies
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Question arises as to whether or not subjects with SD
treated with antidepressants need to be further treated.
This issue requires some examination of our results in
light of results reported in recent literature. First,
according to the hypothesis proposed by Ghaemi [1],
our study indicate that the antidepressant use does not
appear to be associated with improvement in the quality
of life of people with SD; this is in contrast to people
with DE in whom the use of first-line of antidepressants
appears to be associated with a better quality of life.
This finding needs to be confirmed by further studies,
nonetheless, the results are in agreement with the find-
ings of a recent review of clinical randomized trials,
which suggest that there is no clinically significant dif-
ference between antidepressants and placebo in patients
with minor depression [27].
Second, subject with SD and positivity for MDQ
include: a) people with manic episode, fulfilling the cri-
teria for Bipolar Disorders; people with hypomanic epi-
sode (not meeting the criteria for manic episode)
including, b) people with cyclothymic disorder (the
essential features of cyclothymic disorder is a chronic,
fluctuating mood disturbance involving numerous peri-
ods of hypomanic and depressive symptoms), and/or c)
people with hypomanic episode who do not meet the
criteria for cyclothymic disorder (they should be classi-
fied as Bipolar Disorder Not Otherwise Specified).
As with Bipolar Disorder, use of antidepressants in
cyclothymic disorder is typically not recommended,
unless they’re combined with a mood stabilizer. As with
bipolar disorder, taking antidepressants alone can trigger
potentially dangerous manic episodes. Patients with
cyclothymia may switch to type II illness when treated
with antidepressants [28]. Some evidence indicates that
cyclothymia may be also associated with high risk for
switch to rapid cyclicity [29]. Concerning the risk about
switch to mania in people with SD and singular/isolated
episode of hypomania using antidepressants, some stu-
dies suggest a similar risk in Bipolar Disorder Not
Otherwise Specified than in other Bipolar Disordes [30].
Thus, people with SD and mania/hypomania detected
by MDQ positivity are in a group where the use of
antidepressants alone is counterindicated. In our study,
this sub-sample is represented by 7.3% of the total SD
in the community.
Third, a strong association between MDQ positivity,
SD and anxiety disorders as Panic Disorder and Gener-
alized Anxiety Disorders was found in our study. In
these Anxiety disorders, antidepressants are an effica-
cious treatment and SSRI, as previous cited, are indi-
cated as the first choice for treatment as per most
treatment guidelines for anxiety disorders [15-17,31].
Nevertheless it was be found that co-morbidity with
anxiety spectrum disorders and anxiety disorders is
associated with rapid switching [32], thus the use of AD
alone (without mood stabilizers) in people with SD,
MDQ positivity and anxiety disorders may be an option
to be considered with extreme caution. Therefore, the
use of antidepressants in SD and Anxiety disorders
must be preceded by an efficacious screening for mania/
hypomania.
Fourth, a large number of studies have found that
counseling and psychosocial therapies in sub threshold
depression is highly effective, at least in the short-term
[33]. Similarly a brief psychological therapies were effec-
tive for anxiety [33]. Thus, antidepressants do not
appear to have significant advantages for treating SD,
and, it may even be dangerous if used in people with
SD and MDQ positivity. Our results, together with the
results of the recent above cited systematic review [27],
suggest that antidepressants should not be considered
for treatment of individuals with SD.
Limitations of the study
Our study has some significant limitations: first, some of
the phenomena observed have a very low prevalence
despite the use of a large sample of around 4,000, thus
the results need to be considered with caution and con-
firmed by additional surveys. Second, the observational
design is ineffective to account for people’s well being
related to a treatment; in this perspective a community
survey have to be considered only as a source of
hypothesis and these specific results must be considered
only as an heuristic contribute. Third, the sample is
Table 5 Well being (SF-12) by treatment: SD, Sub-threshold Depression (HRDS > 10 without criteria for lifetime
Depressive Episode); DE, Depressive Episode point prevalence; Total Depressive Symptoms = SD plus DE
First line AD Second line AD Only BDZ No AD or BDZ F P
°SD 30.8+/-4.5
(n = 20)
30.4+/-4.3
(n = 7)
28.3+/-4.3
(n = 35)
29.1+/-5.1
(n = 75)
(DF 3,133, 136)
1.3
0.288
*DE 31.6+/-5.6* (n = 17) 30.3+/-4.9 (n = 14) 28.6+/-5.1 (n = 9) 25.8+/-5.1* (n = 15) (DF 3,51,54)
1.8
0.002
§Total depressive symptoms 31.2+/-5.0
(n = 37)
30.3+/-4.7
(n = 21)
28.4+/-4.5
(n = 44)
28.5+/-5.1
(n = 90)
(DF 3, 188,191)
3.0
0.0019
T test Bonferroni 1vs4, 51 DF zP < 0.05, Not Significant differences in the other comparisons; °t test Bonferroni 133 DF, No significant differences; § t test
Bonferroni 188 DF, No significant differences
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representative of certain areas in Italy and is not repre-
sentative of the nation as a whole.
Finally, serious doubts have been raised on the ability
of the MDQ to detect milder bipolar disorders [34]. As
a matter of fact, according to Zimmerman et al [35]
MDQ shows low sensitivity in clinical settings among
cases affected by bipolar disorder. The cross-national
validation studies of MDQ reported good accuracy in
the UK [36], Turkey [37] and Spain [38] and less
encouraging results in France [39]. The validation of the
Italian version of MDQ in the general population [3]
revealed fairly good accuracy, with sensitivity of 0.70,
specificity of 0.87, PPV of 0.47 and NPV of 0.95 (using a
cut-off of seven, as in the present study). Moreover, the
comparison of the MDQ with another screening instru-
ment for Bipolar disorder (Hypomania Checklist (HCL-
32)] showed high consistency [40]
Conclusions
Our study appears to suggest a greater caution in pre-
scribing antidepressants to people with SD, especially
antidepressants with higher risk to induce mania, parti-
cularly to people with concomitant anxiety disorders. In
SD, a well-designed assessment to evaluate the presence
of previous manic or hypomanic symptoms should be
mandatory before prescribing antidepressants.
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